Evidence map›Paper›PMID 30909504›Full record

ReviewInternational journal of molecular sciences2019

Treatment Strategies for Hepatocellular Carcinoma ⁻ a Multidisciplinary Approach.

Isabella Lurje, Zoltan Czigany, Jan Bednarsch, Christoph Roderburg, Peter Isfort, Ulf Peter Neumann, Georg Lurje

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 129 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
129citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

129 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Sorafenib Plus Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2023
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Effect of decoction of Fuzheng Jiedu Xiaoji formula plus chemoembolization on primary liver cancer in patients.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2022
    Trial
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. MicroRNA‑885‑5p regulates cell cycle progression in liver cancer cells.International journal of molecular medicine · 2025
    Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review

69 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Isabella LurjeDepartment of Surgery and Transplantation, University Hospital RWTH Aachen, 52074 Aachen, Germany. ibarth@ukaachen.de.
Zoltan CziganyDepartment of Surgery and Transplantation, University Hospital RWTH Aachen, 52074 Aachen, Germany. zczigany@ukaachen.de.
Jan BednarschDepartment of Surgery and Transplantation, University Hospital RWTH Aachen, 52074 Aachen, Germany. jbednarsch@ukaachen.de.
Christoph RoderburgDepartment of Internal Medicine III, University Hospital RWTH Aachen, 52074 Aachen, Germany. croderburg@ukaachen.de.
Peter IsfortDepartment for Diagnostic and Interventional Radiology, University Hospital RWTH Aachen, 52074 Aachen, Germany. isfort@ukaachen.de.
Ulf Peter NeumannDepartment of Surgery and Transplantation, University Hospital RWTH Aachen, 52074 Aachen, Germany. uneumann@ukaachen.de.
Georg LurjeDepartment of Surgery and Transplantation, University Hospital RWTH Aachen, 52074 Aachen, Germany. glurje@ukaachen.de.

Funding

Excellence Initiative of the German federal and state governments G:(DE-82) ZUK2-SF-OPSF486START-Program of the Faculty of Medicine, RWTH Aachen 136/17START-Program of the Faculty of Medicine, RWTH Aachen 23/19
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is the most common primary tumor of the liver and its mortality is third among all solid tumors, behind carcinomas of the lung and the colon. Despite continuous advancements in the management of this disease, the prognosis for HCC remains inferior compared to other tumor entities. While orthotopic liver transplantation (OLT) and surgical resection are the only two curative treatment options, OLT remains the best treatment strategy as it not only removes the tumor but cures the underlying liver disease. As the applicability of OLT is nowadays limited by organ shortage, major liver resections ⁻ even in patients with underlying chronic liver disease ⁻ are adopted increasingly into clinical practice. Against the background of the oftentimes present chronical liver disease, locoregional therapies have also gained increasing significance. These strategies range from radiofrequency ablation and trans-arterial chemoembolization to selective internal radiation therapy and are employed in both curative and palliative intent, individually, as a bridging to transplant or in combination with liver resection. The choice of the appropriate treatment, or combination of treatments, should consider the tumor stage, the function of the remaining liver parenchyma, the future liver remnant volume and the patient's general condition. This review aims to address the topic of multimodal treatment strategies in HCC, highlighting a multidisciplinary treatment approach to further improve outcome in these patients.

Indexed as

AnimalsCarcinoma, HepatocellularCombined Modality TherapyComorbidityDisease ManagementHumansLiver NeoplasmsTreatment OutcomeHepatocellular carcinomaliver cirrhosisliver resectionliver transplantationmultimodal treatment

Identifiers

PMID30909504
PMCPMC6470895

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.